explore -WSS

explore

author：Wikipedia 2025-09-29 16:35:45 - browse：8317

Have you ever seen a mouse with a set of muscles more appropriate for a bodybuilder or comic book superhero?

Well, 25 years ago, researchers at Johns Hopkins University made it happen. By silencing a gene responsible for producing a protein called myostatin, they directed tiny mouse bodies to grow double the amount of lean muscle they would normally, leading to mice with bulky arms, defined pectorals, and an overall more substantial body mass. They were dubbed “mighty mice.”

Now, biotech startups are hoping to use those findings to create what they believe will be better weight loss medications. In the last several months, multiple companies have disclosed they are testing drugs that preserve or grow muscle while reducing fat, as shown in the updated STAT Obesity Drug Tracker. They hope that their drugs, possibly when used in conjunction with existing obesity treatments, will result in healthier weight loss.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： H5N1 bird flu virus started spreading in cows in Texas in December

explore

WSS

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Diversity in clinical trials starts with building trust, experts say

Bird flu in milk supply is likely coming from asymptomatic cows

Roivant's CEO is a star, but biotech's black hole persists

Cue Health's Covid

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

leisure time

explore

entertainment

Medical leaders decry Supreme Court decision on affirmative action

Smaller biotechs seek to piggyback on weight loss drug boom

Moonlake's readout produced a cash windfall. Risks remain

MultiPlan and major insurers sued for alleged medical price

Apple is now the first public company to be valued at $3 trillion

ADCs take center stage as promising cancer treatments

Psychedelics group wrestles with new pharma identity

H5N1 bird flu found in pasteurized milk: what we know

Apple is now the first public company to be valued at $3 trillion

STAT Summit: The economic case for universal basic health care

hotspot

FTC falls short on scrutinizing hospital mergers, study says

Why does health care cost so much? A reading guide

STAT Summit: Meghan O’Rourke on making chronic illness visible

Roche drug slashes death risk in early

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Diversity in clinical trials starts with building trust, experts say

explore

Wikipedia

knowledge

knowledge